Oral Anti-Diabetic Drug Market

Anti-diabetic drug refers to the medications consumed orally that are prescribed to treat diabetes mellitus (type 2). It treats diabetes (type 2) by lowering down the blood sugar level. These are also known as oral hypoglycemic agents?or?oral antihyperglycemic agents. Oral anti-diabetic drugs are often prescribed as monotherapy but in severe cases, can be given in combination with insulin.
Oral Anti-Diabetic Drug Market contains market size and forecasts of Oral Anti-Diabetic Drug in global, including the following market information:
Global Oral Anti-Diabetic Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Oral Anti-Diabetic Drug Market Sales, 2017-2022, 2023-2028, (K Tons)
Global top five Oral Anti-Diabetic Drug companies in 2021 (%)
The global Oral Anti-Diabetic Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Glimepiride Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Oral Anti-Diabetic Drug include Takeda, Pfizer, Eli Lilly, Janssen Pharmaceuticals, Astellas, Boehringer Ingelheim, Merck And Co., AstraZeneca and Bristol Myers Squibb, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Oral Anti-Diabetic Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Oral Anti-Diabetic Drug Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Tons)
Global Oral Anti-Diabetic Drug Market Segment Percentages, by Type, 2021 (%)
Glimepiride
Gliclazide
Glyburide
Others
Global Oral Anti-Diabetic Drug Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Tons)
Global Oral Anti-Diabetic Drug Market Segment Percentages, by Application, 2021 (%)
Hospital
Research Institual
Global Oral Anti-Diabetic Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Tons)
Global Oral Anti-Diabetic Drug Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Oral Anti-Diabetic Drug revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Oral Anti-Diabetic Drug revenues share in global market, 2021 (%)
Key companies Oral Anti-Diabetic Drug sales in global market, 2017-2022 (Estimated), (K Tons)
Key companies Oral Anti-Diabetic Drug sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Takeda
Pfizer
Eli Lilly
Janssen Pharmaceuticals
Astellas
Boehringer Ingelheim
Merck And Co.
AstraZeneca
Bristol Myers Squibb
Novartis
Sanofi
Abbott
Biocon